Results 21 to 30 of about 80,161 (286)

Protective Effects of Sodium-Glucose Transporter 2 Inhibitors on Atrial Fibrillation and Atrial Flutter: A Systematic Review and Meta- Analysis of Randomized Placebo-Controlled Trials. [PDF]

Front Endocrinol (Lausanne), 2021
Background Hyperglycemia is associated with an increased risk of developing atrial fibrillation (AF) and atrial flutter (AFL). Sodium-glucose transporter 2 inhibitors (SGLT2i) have been reported to prevent AF/AFL in some studies, but not others ...
Li D, Liu Y, Hidru TH, Yang X, Wang Y, Chen C, Li KHC, Tang Y, Wei Y, Tse G, Xia Y.   +10 more
europepmc   +2 more sources

Sodium-glucose co-transporter 2 inhibitors beyond diabetes

Australian Prescriber, 2022
Sodium-glucose co-transporter 2 (SGLT2) inhibitors lower blood glucose by reducing the reabsorption of glucose in the kidney. They are a second-line therapy for type 2 diabetes. During clinical trials it was noticed that SGLT2 inhibitors had favourable effects on cardiovascular and renal disease.
Williams, Dimity L., Rofail, Serena, Atherton, John J.   +2 more
openaire   +5 more sources

Glycemic Efficacy and Metabolic Consequences of an Empagliflozin Add-on versus Conventional Dose-Increasing Strategy in Patients with Type 2 Diabetes Inadequately Controlled by Metformin and Sulfonylurea [PDF]

Endocrinology and Metabolism, 2020
Background We assessed the glucose-lowering efficacy of adding empagliflozin versus dose escalating existing medications in patients with uncontrolled type 2 diabetes (T2D).
Yujin Shin, Ji Hye Moon, Ho Jun Chin, Ele Ferrannini, Soo Lim   +4 more
doaj   +1 more source

Sodium-glucose co-transporter-2 inhibitors and epicardial adiposity

European Journal of Pharmaceutical Sciences, 2023
Epicardial adipose tissue is a layer of adipocytes that physiologically surround the myocardium and play some physiologic roles in normal heart function. However, in pathologic conditions, the epicardial adipose tissue can present a potent cardiac risk factor that is capable of impairing heart function through several pathways, increasing the risk of ...
Habib Yaribeygi, Mina Maleki, Alexandra E. Butler, Tannaz Jamialahmadi, Amirhossein Sahebkar   +4 more
openaire   +2 more sources

The clinical cases of ketoacidosis in patients with 2 type diabetes treated with inhibitors of sodium-glucose co-transporter

Клинический разбор в общей медицине, 2021
The diabetic ketoacidosis (DKA) is the most frequent urgent condition in patients with diabetes mellitus which requires hospitalization and results to mortality. The most common causes of DKA are the presence of concomitant diseases in diabetic patients,
Diana Sh. Avzaletdinova , Ilmira Z. Khabibulluna, Olga Y. Ibragimova , Tatiana V. Morugova   +3 more
doaj   +1 more source

Genito-urinary infection risk estimates during sodium glucose co-transporter 2 inhibitor exposure in everyday clinical practice. [PDF]

Farmacja Polska, 2021
Genito-urinary infection risk estimates during sodium glucose co-transporter 2 inhibitor exposure in everyday clinical practice. Type 2 diabetes mellitus, cardiovascular diseases and congestive heart failure are known to be a cause of growing ...
Beata Jacuś, Mirosława Kowalkowska, Paweł Miękus, Grzegorz Grześk   +3 more
doaj   +1 more source

Impact of Diabetes on The Effects Of Sodium Glucose Co-Transporter-2 (SGLT2) Inhibitors on Kidney Outcomes: Collaborative Meta-Analysis of Large Placebo-Controlled Trials

The Lancet, 2022
Background Large trials have shown sodium glucose co-transporter-2 (SGLT2) inhibitors reduce risk of kidney and cardiovascular outcomes in patients with heart failure and chronic kidney disease (CKD), but were not powered to assess outcomes in patients ...
C. Baigent, J. Emberson, R. Haynes, W. Herrington, P. Judge, M. Landray, Kaitlin J. Mayne, S. Ng, D. Preiss, A. Roddick, N. Staplin, D. Zhu, S. Anker, Deepak L. Bhatt, M. Brueckmann, J. Butler, D. Cherney, Jennifer B. Green, S. Hauske, H. Heerspink, S. Inzucchi, M. Jardine, Chih-Chin Liu, K. Mahaffey, Finnian R. McCausland, D. McGuire, J. McMurray, B. Neal, B. Neuen, M. Packer, V. Perkovic, M. Sabatine, S. Solomon, M. Vaduganathan, C. Wanner, D. Wheeler, S. Wiviott, F. Zannad   +37 more
semanticscholar   +1 more source

SGLT2 Inhibitors for Nephrologists

European Medical Journal Nephrology, 2022
Angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers are the mainstay of therapy for the prevention of progressive renal damage in diabetic and non-diabetic kidney diseases, especially glomerulonephritides.
Mufti Baleegh-ur-Raheem Mahmood, Sidra Farishta   +1 more
doaj   +1 more source

Sodium glucose co-transport 2 inhibitors for gout treatment

Discoveries, 2022
Hyperuricemia remains the most prevalent cause of gout. Gout patients present with joint inflammation and uric acid crystals deposition manifesting as tophi. The association of gout with increased risk of insulin resistance, diabetes, metabolic disorders, increased cardiometabolic risk, and kidney disease is well established.
Somagutta, Manoj Kumar Reddy, Luvsannyam, Enkhmaa, Jain, Molly, Cuddapah, Gaurav Venkat, Pelluru, Sandeep, Mustafa, Nafisa, Nasereldin, Duaa S., Pendyala, Siva K., Jarapala, Nagendrababu, Padamati, Bhavani   +9 more
openaire   +2 more sources

All‐cause mortality and cardiovascular outcomes with sodium‐glucose Co‐transporter 2 inhibitors, glucagon‐like peptide‐1 receptor agonists and with combination therapy in people with type 2 diabetes

Diabetes, obesity and metabolism, 2023
To assess the relationship of sodium‐glucose cotransporter‐2 inhibitors (SGLT2i), glucagon‐like peptide‐1 receptor analogues (GLP‐1RA) and their combination (SGLT2i + GLP‐1RA) with 5‐year risk of all‐cause mortality, hospitalization and cardiovascular ...
David R. Riley, H. Essa, P. Austin, Frank G. Preston, Isatu Kargbo, G. H. Ibarburu, Raman Ghuman, D. Cuthbertson, G. Lip, U. Alam   +9 more
semanticscholar   +1 more source